Summary
This 8-K filing from Gilead Sciences, Inc., dated October 28, 2003, primarily serves to attach a press release announcing the company's financial results for the quarter and nine months ended September 30, 2003. Investors should note that the company is presenting non-GAAP financial measures, which management uses to provide a clearer view of ongoing operating results and trends. These adjustments are made to exclude unusual items, specifically an in-process research and development charge related to the Triangle Pharmaceuticals acquisition in January 2003 and a vendor dispute settlement reimbursement in September 2003. Management believes these exclusions offer valuable insight into the company's core business performance, unaffected by these significant, infrequent transactions. The filing itself is quite brief, with its main purpose being the dissemination of the earnings press release (Exhibit 99.1). Investors looking for detailed financial performance, including revenue, net income, and specific product performance, will need to refer to the content of that attached press release, which is not directly included in this 8-K document. The CFO, John F. Milligan, signed off on the filing.
Key Highlights
- 1Gilead Sciences, Inc. filed an 8-K on October 28, 2003, to report financial results for the quarter and nine months ended September 30, 2003.
- 2The primary content of the filing is an attached press release (Exhibit 99.1) containing the earnings announcement.
- 3Gilead is presenting non-GAAP financial measures, excluding specific unusual items for clarity.
- 4Excluded items include an in-process R&D charge from the Triangle Pharmaceuticals acquisition (January 2003).
- 5Excluded items also include a reimbursement from a vendor contractual dispute settlement (September 2003).
- 6Management believes these adjustments provide better insight into the company's core business performance.
- 7John F. Milligan, Executive Vice President and CFO, signed the filing.